Evaluation of Dose and Safety of AAV7m8 and AAV8BP2 in the Non-Human Primate Retina

Human Gene Therapy

Volumn 28, Issue 2, 2017, Pages 154-167

  Ramachandran, Pavitra S ^a   Lee, Vivian ^a   Wei, Zhangyong ^a   Song, Ji Yun ^a   Casal, Giulia ^a   Cronin, Therese ^a   Willett, Keirnan ^a   Huckfeldt, Rachel ^a   Morgan, Jessica I W ^a   Aleman, Tomas S ^a   Maguire, Albert M ^a   Bennett, Jean ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

AAV; animal models; gene therapy; non human primate; retina

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR EYE CHAMBER; CONTROLLED STUDY; GENETIC TRANSDUCTION; IMMUNOGENICITY; MACACA FASCICULARIS; MOUSE; NONHUMAN; PRIMATE; RETINA BIPOLAR GANGLION CELL; RETINA CONE; RETINA DISEASE; REVIEW; SAFETY; SEROTYPE; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; ADMINISTRATION AND DOSAGE; ANIMAL; CLASSIFICATION; CYTOLOGY; DEPENDOPARVOVIRUS; EVALUATION STUDY; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; METABOLISM; RETINA; RETINAL DEGENERATION;

ANIMALS; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; HUMANS; PRIMATES; RETINA; RETINAL DEGENERATION;

EID: 85012169812     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2016.111     Document Type: Review

References (32)

1. Testa F, Maguire AM, Rossi S, et al. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. Ophthalmology 2013; 120:1283-1291.
2. Bennett J, Ashtari M, Wellman J, et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med 2012; 4: 120ra115.
3. Bennett J, Wellman J, Marshall KA, et al. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on Phase 1 trial. Lancet 2016;388:661-672.
4. Grimm D, Zolotukhin S. E Pluribus Unum: 50 years of research, millions of viruses, and one goal -Tailored acceleration of AAV evolution. Mol Ther 2015;23:1819-1831.
5. Santiago-Ortiz J, Ojala DS, Westesson O, et al. AAV ancestral reconstruction library enables selection of broadly infectious viral variants. Gene Ther 2015;22:934-946.
6. Yin L, Greenberg K, Hunter JJ, et al. Intravitreal injection of AAV2 transduces macaque inner retina. Invest Ophthalmol Vis Sci 2011;52:2775-2783.
7. Dalkara D, Kolstad KD, Caporale N, et al. Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. Mol Ther 2009;17:2096-2102.
8. Tolmachova T, Tolmachov OE, Barnard AR, et al. Functional expression of Rab escort protein 1 following AAV2-mediated gene delivery in the retina of choroideremia mice and human cells ex vivo. J Mol Med 2013;91:825-837.
9. Bennicelli J, Wright JF, Komaromy A, et al. Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2- mediated gene transfer. Mol Ther 2008;16:458-465.
10. Dalkara D, Byrne LC, Klimczak RR, et al. In vivodirected evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med 2013;5: 189ra176.
11. Gaub BM, Berry MH, Holt AE, et al. Restoration of visual function by expression of a light-gated mammalian ion channel in retinal ganglion cells or ON-bipolar cells. Proc Natl Acad Sci U S A 2014;111:E5574-5583.
12. Mace E, Caplette R, Marre O, et al. Targeting channelrhodopsin-2 to ON-bipolar cells with vitreally administered AAV Restores ON and OFF visual responses in blind mice. Mol Ther 2015;23:7-16.
13. Lagali PS, Balya D, Awatramani GB, et al. Lightactivated channels targeted to ON bipolar cells restore visual function in retinal degeneration. Nat Neurosci 2008;11:667-675.
14. Scalabrino ML, Boye SL, Fransen KM, et al. Intravitreal delivery of a novel AAV vector targets ON bipolar cells and restores visual function in a mouse model of complete congenital stationary night blindness. Hum Mol Genet 2015;24:6229-6239.
15. Cronin T, Vandenberghe LH, Hantz P, et al. Efficient transduction and optogenetic stimulation of retinal bipolar cells by a synthetic adenoassociated virus capsid and promoter. EMBO Mol Med 2014;6:1175-1190.
16. Stieger K, Colle MA, Dubreil L, et al. Subretinal delivery of recombinant AAV serotype 8 vector in dogs results in gene transfer to neurons in the brain. Mol Ther 2008;16:916-923.
17. Liu X, Yan Z, Luo M, et al. Species-specific differences in mouse and human airway epithelial biology of recombinant adeno-associated virus transduction. Am J Respir Cell Mol Biol 2006;34: 56-64.
18. Vandenberghe LH, Bell P, Maguire AM, et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med 2011;3:88ra54.
19. Amado D, Mingozzi F, Hui D, et al. Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindness. Sci Transl Med 2010;2:21ra16.
20. Schindelin J, Arganda-Carreras I, Frise E, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods 2012;9:676-682.
21. Hippert C, Graca AB, Barber AC, et al. Muller glia activation in response to inherited retinal degeneration is highly varied and disease-specific. PLOS ONE 2015;10:e0120415.
22. MacLaren RE, Bennett J, Schwartz SD. Gene therapy and stem cell transplantation in retinal disease: the new frontier. Ophthalmology 2016; 123:S98-S106.
23. Borras T, Elliott R, Buie L, et al. Transgene targeting of the iris pigment epithelium (IPE) to study and potentially treat pseudoexfoliation glaucoma. Invest Ophthalmol Vis Sci 2014;55: 5667-5667.
24. Hou XR, Miao H, Tao Y, et al. Expression of cytokines on the iris of patients with neovascular glaucoma. Acta Ophthalmol 2015;93:e100-104.
25. El Sanharawi M, Touchard E, Benard R, et al. Long-term efficacy of ciliary muscle gene transfer of three sFlt-1 variants in a rat model of laserinduced choroidal neovascularization. Gene Ther 2013;20:1093-1103.
26. Grimm D, Zhou S, Nakai H, et al. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood 2003;102: 2412-2419.
27. Black A, Vasireddy V, Chung DC, et al. Adenoassociated virus 8-mediated gene therapy for choroideremia: preclinical studies in in vitro and in vivo models. J Gene Med 2014;16:122-130.
28. Kay CN, Ryals RC, Aslanidi GV, et al. Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors. PLOS ONE 2013;8:e62097.
29. Petrs-Silva H, Dinculescu A, Li Q, et al. Highefficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther 2009;17:463-471.
30. Petrs-Silva H, Dinculescu A, LiQ, et al. Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 2011;19:293-301.
31. Mowat FM, Gornik KR, Dinculescu A, et al. Tyrosine capsid-mutant AAV vectors for gene delivery to the canine retina from a subretinal or intravitreal approach. Gene Ther 2014;21:96-105.
32. Vandenberghe LH, Bell P, Maguire AM, et al. AAV9 targets cone photoreceptors in the nonhuman primate retina. PLOS ONE 2013;8:e53463.